A novel oncolytic adenovirus expressing escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 4, 2010, Pages 487-495

  Zhang, Jufeng ^a,b   Wei, Fang ^a   Wang, Huiping ^a   Li, Huiming ^a   Qiu, Wei ^a   Ren, Pengkang ^a   Chen, Xiafang ^a   Huang, Qian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

cytosine deaminase gene; gene therapy; human telomerase reverse transcriptase gene promoter; oncolytic adenovirus

Indexed keywords

ADENOVIRUS VECTOR; CYTOSINE DEAMINASE; E1A PROTEIN; FLUCYTOSINE; FLUOROURACIL; ONCOLYTIC ADENOVIRUS; TELOMERASE REVERSE TRANSCRIPTASE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; FIBROBLAST; GENE CASSETTE; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMEDIATE EARLY GENE; IN VITRO STUDY; IN VIVO STUDY; LUNG TUMOR; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SOLID TUMOR; TARGET CELL DESTRUCTION; TUMOR CELL; TUMOR CELL LINE; TUMOR GROWTH; VIRAL GENE THERAPY; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIMETABOLITES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMBINED MODALITY THERAPY; CYTOMEGALOVIRUS; CYTOSINE DEAMINASE; DERMIS; ESCHERICHIA COLI; FIBROBLASTS; FLUCYTOSINE; GENE THERAPY; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PRODRUGS; PROMOTER REGIONS, GENETIC; TELOMERASE; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956151114     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0752     Document Type: Article

References (25)

1. Amato RJ, Drury N, Naylor S, et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): A phase 2 trial. J Immunother 2008;31:577.
2. Forsyth P, Roldán G, George D, et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008;16:627.
3. Kemeny N, Brown K, Covey A, et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006;17:1214.
4. Laurie SA, Bell JC, Atkins HL, et al. Phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 2006;12: 2555.
5. Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions. Cancer Res 2007;67:429.
6. Myers R, Harvey M, Kaufmann TJ, et al. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum Gene Ther 2008;19:690.
7. Haviv YS, Curiel DT. Engineering regulatory elements for conditionally-replicative adeno-viruses. Curr Gene Ther 2003;3:357.
8. Uchino J, Takayama K, Harada A, et al. Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment. Cancer Gene Ther 2005;12:737.
9. Chiocca EA, Abbed KM, Tatter S. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004;10:958.
10. Nemunaitis J, Senzer N, Sarmiento S. A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Ther 2007;14:885.
11. Dix BR, Edwards SJ, Braithwaite AW. Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J Virol 2001;75:5443.
12. Geoerger B, Grill J, Opolon P, et al. Oncolytic Activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 2002;62:764.
13. Gu J, Andreeff M, Roth JA, et al. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 2002;9:30.
14. Meyerson M. Role of telomerase in normal and cancer cells. J Clin Oncol 2000;18:2626.
15. Huang Q, Zhang X, Wang H, et al. A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res 2004;10:1439.
16. Irving J, Wang Z, Powell S, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 2004;11:174.
17. Kim E, Kim JH, Shin HY, et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003;14:1415.
18. Lanson NA Jr, Friedlander PL, Schwarzenberger P, et al. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumorselective tumor lysis. Cancer Res 2003;63:7936.
19. Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003;63:3181.
20. Miller CR, Williams CR, Buchsbaum DJ, et al. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 2002;62:773.
21. Bentires-Alj M, Hellin AC, Lechanteur C, et al. Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther 2000;7:20.
22. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002;62:4968.
23. Zhang Q, Nie M, Sham J, et al. Effective gene-viral therapy for telomerase-positive cancers by selective replicativecompetent adenovirus combining with endostatin gene. Cancer Res 2004;64:5390.
24. Lohr F, Huang Q, Hu K, et al. Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. Clin Cancer Res 2001;7: 3625.
25. Wildner O, Hoffmann D, Jogler C, et al. Comparison of HSV-1 thymidine kinase-dependent and independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Ther 2003;10:791.